Nymox Announces New Positive Results At 54 Months In Long Term Study Of NX-1207 For Benign Prostatic Hyperplasia

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced new positive results from a long term outcome study of NX-1207 for benign prostatic hyperplasia (BPH). The study evaluated symptomatic progress of U.S. patients involved in the Company’s two Phase 1-2 studies initiated in 2003.

More: continued here

Filed under: Prostate on May 15th, 2008